scholarly journals Are Bethesda III Thyroid Nodules More Aggressive than Bethesda IV Thyroid Nodules When Found to Be Malignant?

Cancers ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 2563
Author(s):  
Sena Turkdogan ◽  
Marc Pusztaszeri ◽  
Veronique-Isabelle Forest ◽  
Michael P. Hier ◽  
Richard J. Payne
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Thyroid Nodules ◽  
Molecular Genetic ◽  
Hospital Setting ◽  
Retrospective Chart Review ◽  
Tertiary Hospital ◽  
P Value ◽  
Papillary Thyroid ◽  
Genetic Test Results

The Bethesda classification system for thyroid fine needle aspirate (FNA) is used to predict the risk of malignancy and to guide the management of thyroid nodules. We postulated that thyroid malignancies characterized as Bethesda III on FNA have more aggressive features than those classified as Bethesda IV. A retrospective chart review was performed to identify those who underwent thyroid surgery at a single tertiary hospital setting between 2015 and 2020. Associations between Bethesda category, molecular genetic test results, and histopathologic findings were examined. Out of 628 surgeries that were performed, 199 (54.2%) Bethesda III nodules and 216 (82.8%) Bethesda IV nodules were malignant. Of those that were malignant, 37 (18.6%) and 22 (10.2%) Bethesda III and Bethesda IV nodules showed aggressive features, respectively (p value = 0.014). There was a proportionally increased number of aggressive features in extra-thyroidal extension, lymph nodes metastasis, and all aggressive subtypes of papillary thyroid cancer in the Bethesda III category. Although Bethesda IV nodules are much more likely to be malignant (p value = 0.002), our study suggests that Bethesda III nodules that are resected are more likely to have aggressive features than Bethesda IV nodules, with a statistically significant increase in the solid variant of papillary thyroid cancer and lymph node metastasis.

Serum osteopontin can improve papillary thyroid cancer risk assessment of Bethesda III thyroid nodules: a preliminary study

2021 ◽  
Author(s):  
Taha Ulutan Kars ◽  
Mustafa Kulaksizoglu ◽  
İbrahim Kılınç
Keyword(s):  
Thyroid Cancer ◽  
Cancer Risk ◽  
Papillary Thyroid Cancer ◽  
Thyroid Nodules ◽  
Cancer Risk Assessment ◽  
Papillary Thyroid ◽  
Operating Characteristics ◽  
Discriminative Performance ◽  
Thyroid Cancer Risk ◽  
Preliminary Study

Objective: Thyroid cancer can be detected in 5–10% of patients with thyroid nodules. Management may be a challenge if fine-needle aspiration biopsy yields Bethesda III findings. Most of these cases undergo surgery and are ultimately found benign. Our aim was to evaluate whether serum osteopontin can accurately estimate thyroid cancer risk in cases with cytologically Bethesda III thyroid nodules and, thereby, decrease the number of unnecessary surgical interventions. Design and Methods: We obtained blood samples of cases with repeated cytologically Bethesda III thyroid nodules before surgery, and followed up the pathology results after thyroidectomy. We evaluated serum osteopontin from 36 patients with papillary thyroid cancer and compared them with 40 benign cases. Results: Serum osteopontin levels in patients with papillary thyroid cancer are significantly higher than in benign cases (mean serum osteopontin: 10.48 ± 3.51 ng/mL vs 6.14 ± 2.29 ng/mL, p<0.001). The area under the receiver operating characteristics curve was 0.851, suggesting that serum osteopontin could have considerable discriminative performance. Conclusions: In our preliminary study, high serum osteopontin levels can predict the risk of papillary thyroid cancer in thyroid nodules with Bethesda III cytology. Further studies are necessary to confirm these findings.

Molecular genetic factors in the development of papillary thyroid cancer in the Kazakh population

2018 ◽  
Vol 64 (3) ◽  
Author(s):  
Mayra Zhaksimanovna Espenbetova ◽  
Natalya Egorovna Glushkova ◽  
Ainur Serikovna Krykpayeva
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Case Control Study ◽  
Effective Means ◽  
Molecular Genetic ◽  
Control Group ◽  
Papillary Thyroid ◽  
Similar Work ◽  
Kazakh Population ◽  
Control Study

Introduction. In the last decade several population studies on the association of the genes NKX2-1 and FOXE1 with sporadic papillary thyroid cancer were conducted. In the Kazakh population of similar work to date were not conducted. The aim of this study was to study the genetic association of the FOXE1 (rs9655313) and NKX2-1 (rs944289) oncomarkers with papillary thyroid cancer in the Kazakh population. Materials and methods. We conducted a case-control study that allows us to retrospectively evaluate the association of NKX2-1 and FOXE1 genes and papillary thyroid cancer. Results. The frequency distribution of FOXE1 rs965513 polymorphism in the group of papillary thyroid cancer and the control group detected by healthy individuals was significantly different (χ2 = 100.09, D.f. = 2, p = 0.000). In the group of cases, the AA genotype (17.5%) was in three times more often compared with the control group (5.1%). The GG variant had a lower frequency in the group of persons of papillary thyroid cancer (37.9%) against the control group (61.4%), the odds ratio (OR) in the FOXE1 rs965513 group was 2.367. The distribution of the NKX2-1 (rs944289) polymorphism frequencies in the compared groups of values were significantly different (χ2 = 100.09, D.f. = 2, p = 0.000). In the group of cases, the genotype of TT (30.5%) against the control group (20.7%) was 1.5 times more common. The SS variant had a lower frequency of occurrence in the group of persons of papillary thyroid cancer (19.8%) against the control group (28.9%), OR in NKX2-1 (rs944289) group was 1.46. Conclusion. Carrying out screening for carriers of FOXE1 rs965513 and NKX2-1 (rs944289) can become an effective means of early diagnosis with a high frequency of its spread and associations with cases of papillary thyroid cancer in the Kazakh population.

scholarly journals Papillary thyroid cancer in an adolescent with a toxic single nodular goiter

2017 ◽  
Vol 63 (2) ◽  
pp. 114-116 ◽  
Author(s):  
Olga S. Rogova ◽  
Goar F. Okminyan ◽  
Lubov N. Samsonova ◽  
Elena V. Kiseleva ◽  
Oleg Yu. Latyshev ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Thyroid Nodule ◽  
Papillary Thyroid Cancer ◽  
Thyroid Nodules ◽  
Fine Needle Aspiration Biopsy ◽  
Nodular Goiter ◽  
Needle Aspiration ◽  
Papillary Thyroid ◽  
Risk Of Malignancy ◽  
Functional Autonomy

The rate of nodular goiter in children ranges from 0.05 to 5.1%; in this case, the risk of thyroid cancer in childhood amounts to 3―70% of all cases of thyroid pathology. Therefore, the main issue is the differential diagnosis of a nosological variant of a thyroid nodule, which defines the optimal therapeutic tactics for a particular patient. The risk of malignancy is traditionally believed to be low in the case of decompensated functional autonomy of a thyroid nodule; therefore, the need for fine needle aspiration biopsy (FNAB) followed by cytomorphological analysis of the aspirate is avoided in most cases. The presented clinical case demonstrates papillary cancer in an adolescent with a toxic single nodular goiter. A thyroid ultrasound examination revealed a nodular lesion in the boy. An increase in the thyroid size and thyrotoxicosis manifestation occurred 3 years later. A cytomorphological study identified follicular neoplasia; scintigraphy revealed a hot nodule. Surgical treatment was planned. Antithyroid therapy was prescribed to prepare for surgery. After compensation of thyrotoxicosis, hemithyroidectomy was performed. A histological examination diagnosed papillary thyroid cancer, which required repeated thyroidectomy followed by radioiodine I131 ablation. The postoperative period was uneventful; the patient well tolerated suppressive levothyroxine therapy. Therefore, the presence of a toxic single nodular goiter does not exclude thyroid cancer, which defines the need to discuss the indications for FNAB of thyroid nodules in children.

scholarly journals Detection of STRN‐ALK fusion in thyroid nodules with indeterminate cytopathology facilitates papillary thyroid cancer diagnosis

2020 ◽  
Author(s):  
Magdalena Jurkiewicz ◽  
Adela Cimic ◽  
Vundavalli V. Murty ◽  
Jennifer H. Kuo ◽  
Susan Hsiao ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Cancer Diagnosis ◽  
Thyroid Nodules ◽  
Papillary Thyroid

Thyroid Cancer in Uremic Patients

1998 ◽  
Vol 84 (4) ◽  
pp. 504-505 ◽  
Author(s):  
Takuya Hatada ◽  
Kaoru Okada ◽  
Hiromitsu Ishii ◽  
Shigetoshi Ichii ◽  
Joji Utsunomiya
Keyword(s):  
Thyroid Cancer ◽  
Secondary Hyperparathyroidism ◽  
Papillary Thyroid Cancer ◽  
Thyroid Nodules ◽  
Correct Diagnosis ◽  
Benign Nodule ◽  
Papillary Thyroid ◽  
Uremic Patients

Background The combination of thyroid cancer and secondary uremic hyperparathyroidism has thus far been reported in only 25 cases. Methods Here we report our experience of 19 patients with secondary hyperparathyroidism who underwent parathyroidectomy. Results Thyroid nodules were present in five patients (26.3%), including one with a benign nodule and four with papillary thyroid cancer (21.1%). Conclusion Our experience suggests that, in order to make a correct diagnosis, clinicians should consider the possibility of thyroid cancer in uremic patients with secondary hyperparathyroidism.

Predictors of incomplete response to therapy among Filipino patients with papillary thyroid cancer in a tertiary hospital

2015 ◽  
Vol 39 (1) ◽  
pp. 55-62
Author(s):  
E. S. Mendoza ◽  
A. A. Lopez ◽  
V. A. U. Valdez ◽  
E. C. Cunanan ◽  
B. J. Matawaran ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Tertiary Hospital ◽  
Response To Therapy ◽  
Papillary Thyroid ◽  
Incomplete Response

scholarly journals A clinical case of hereditary papillary thyroid carcinoma associated with a germline DICER1 gene mutation

2017 ◽  
Vol 63 (5) ◽  
pp. 320-324
Author(s):  
Svetlana A. Babinskaya ◽  
Natalia Yu. Kalinchenko ◽  
Alexey A. Ilyin ◽  
Natalia V. Severskaya ◽  
Irina V. Chebotareva ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Gene Mutation ◽  
Multinodular Goiter ◽  
Clinical Case ◽  
Stop Codon ◽  
Molecular Genetic ◽  
Premature Stop Codon ◽  
Papillary Thyroid ◽  
Reading Frame

Here, we report a clinical case of isolated papillary thyroid cancer associated with a germline DICER1 gene mutation in a boy and his father. The father underwent surgery for a euthyroid multinodular goiter at the age of 7 and 9 years. On examination at the age of 27 years, he was diagnosed with papillary thyroid cancer. At the age of 7 years, the boy was suspected of having a multinodular goiter (based on thyroid ultrasonography findings); he underwent total thyroidectomy. A histological examination of the surgical material revealed encapsulated papillary carcinoma. Neither boy nor his father had been exposed to radiation or chemotherapy before the diagnosis of papillary thyroid cancer. To clarify the etiology of disease, a molecular genetic testing was performed using next-generation sequencing (NGS). The proband and his parent had a heterozygous thymine deletion in the exon 4 at position 380, which led to a shift in the reading frame with the formation of a premature stop codon (c.380delT p.L127QfsX3).

scholarly journals Immunological aspects of papillary thyroid cancer. What's new?

2021 ◽  
Vol 16 (4) ◽  
pp. 14-18
Author(s):  
Ekaterina A. Troshina ◽  
Maria A. Terekhova ◽  
Ravida R. Akhmatova
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Malignant Tumors ◽  
Molecular Genetic ◽  
Endocrine Tumors ◽  
Papillary Thyroid ◽  
Area Of Interest ◽  
Oncological Diseases ◽  
The Common ◽  
Complex Relationships

Studying of the common links of pathogenesis of endocrine, autoimmune and oncological diseases is the area of interest of researchers from all countries of the world. Comprehension of artificially created mutual influences of molecular-genetic, immune factors that underlie the development and progression of endocrine tumors, primarily thyroid cancer, is important for creation and application of innovative treatment methods in oncoendocrinology.Today, the question of considering autoimmune diseases as a potential cause of oncological processes or on the contrary to consider them as protective conditions in some types of malignant tumors, remains controversial.In particular, autoimmune thyropathies and papillary thyroid cancer is an interesting model for studying these complex relationships. . The purpose of this article is to discuss accumulated experience, review the literature devoted to the study of immunological aspects in the pathogenesis of papillary thyroid cancer, reconsider obtained material and form a conclusion.

scholarly journals Altered levels of circulating nuclear and mitochondrial DNA in patients with Papillary Thyroid Cancer

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Ewelina Perdas ◽  
Robert Stawski ◽  
Krzysztof Kaczka ◽  
Dariusz Nowak ◽  
Maria Zubrzycka
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Dna Content ◽  
Thyroid Nodules ◽  
High Specificity ◽  
Fine Needle Biopsy ◽  
Cancer Type ◽  
Papillary Thyroid ◽  
Roc Curve Analysis ◽  
Method Of Evaluation

Abstract Papillary thyroid cancer is the most common thyroid cancer type. However, diagnostics based on fine needle biopsy cannot make a definitive diagnosis in 25% of thyroid nodules. Additionally, approximately 70% to 80% of thyroid lobectomies performed just for diagnostic purposes are benign. Despite this, biopsy still remains the main method of evaluation of thyroid nodules. Cell-free DNA (cf-DNA) measurement could give a new diagnostic opportunities which may reduce the number of unnecessary thyroid procedures. In this study, using a qPCR, we have examined the nuclear cf-DNA and mitochondrial cf-DNA in the plasma of 32 patients. We have found that the level of nuclear cf-DNA is almost 2-fold increased (median 3 089 vs. 1 872, p = 0.022), whereas mitochondrial cf-DNA content was significantly decreased in respect to healthy controls (median 44 992 vs. 92 220, p = 0.010). The ROC curve analysis showed high specificity for nuclear cf-DNA and mitochondrial cf-DNA, which may serve as a useful tool to decrease the number of unneeded surgeries. Our study reports the first epidemiological evidence for lower mitochondrial cf-DNA content in the patient group, what suggests that apart from nuclear cf-DNA also mitochondrial cf-DNA is affected by disease development.

Sign in / Sign up

Export Citation Format

Share Document